Temozolomide (TMZ) is the standard of care for GBM, but it still has limitations and unsatisfactory outcomes, particularly in patients with tumor cells expressing the O(6)-methyguanine-DNA-methyltransferase (MGMT) [1,23]. This evidence concerns the gene MGMT and neoplasm.